- Home
- CDLX vs FENC Comparison
CDLX vs FENC Comparison
Compare CDLX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDLX | FENC |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3M | 266.4M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CDLX | FENC |
|---|---|---|
| Price | $1.05 | $6.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.25 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.2M | 194.5K |
| Earning Date | 03-04-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | $44,642,000.00 |
| Revenue This Year | N/A | $75.81 |
| Revenue Next Year | $0.98 | $25.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $4.68 |
| 52 Week High | $3.28 | $9.92 |
Technical Indicators
Market Signals| Indicator | CDLX | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 62.56 | 36.33 |
| Support Level | $1.00 | N/A |
| Resistance Level | $1.26 | $9.09 |
| Average True Range (ATR) | 0.11 | 0.47 |
| MACD | 0.04 | -0.17 |
| Stochastic Oscillator | 76.65 | 20.93 |
Price Performance
Historical ComparisonAbout CDLX Cardlytics Inc.
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.